ArticlesPlasma brain natriuretic peptide in assessment of acute dyspnoea
References (19)
- et al.
The use of exercise testing and other methods in the investigation of dyspnea
Clin Chest Med
(1984) - et al.
Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction
Lancet
(1993) - et al.
Brain natriuretic peptide as a novel cardiac hormone in humans
J Clin Invest
(1991) Atrial natriuretic peptide: synthesis, release, and metabolism
Pharm Rev
(1992)- et al.
Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
Circulation
(1993) - et al.
Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma.
J Clin Endocrinol Metab
(1986) - et al.
Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure
J Clin Endocrinol Metab
(1993) - et al.
Assay of endopeptidase- 24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors
Clin Chem
(1992) - et al.
Validation of the "orange slice" method for estimating left ventricular volumes
(1993)
There are more references available in the full text version of this article.
Cited by (486)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2022, Journal of the American College of CardiologyDisproportionately low BNP levels in patients of acute heart failure with preserved vs. reduced ejection fraction
2021, International Journal of CardiologyA novel potential-resolved electrochemiluminescence immunosensor for the simultaneous determination of brain natriuretic peptide and cardiac troponin I
2020, Sensors and Actuators, B: ChemicalThe value of B-type natriuretic peptide plasma concentrations in very old people with chronic peripheral oedema
2020, Archives of Cardiovascular DiseasesCitation Excerpt :Recognition of CHF is a major step towards implementing appropriate treatments and improving the prognosis of patients with CPE of cardiac origin. The clinical utility of BNP plasma concentration has been studied extensively in patients with acute dyspnoea, and especially in the context of emergencies [11–13]. A large consensus established that values < 100 pg/mL rule out the diagnosis of heart failure, and that values > 400 pg/mL are a strong argument for this diagnosis [17].
Arterial pH selectively predicts critical care needs in emergency department obese patients with acute dyspnea: A prospective comparative study
2019, American Journal of Emergency Medicine
Copyright © 1994 Published by Elsevier Ltd.